Hero Image

Immunotherapy for Lung Cancer: When and How It Works

Immunotherapy for lung cancer is changing care by training your immune system to find and fight tumor cells.

In this guide, you’ll learn how it works, who’s a good candidate, when it’s chosen over chemotherapy, expected benefits and risks, and what treatment looks like day to day.

Understanding Immunotherapy for Lung Cancer

Immunotherapy helps your body’s defense system recognize cancer as a threat and attack it. Unlike chemotherapy, which kills fast-growing cells directly, immunotherapy removes the immune system’s “brakes” so T cells can target tumors more effectively. For an overview, see the National Cancer Institute’s explanation of immunotherapy here.

For many people with advanced non-small cell lung cancer (NSCLC), this approach can lead to longer control of the disease and, in some cases, durable remissions. It may also be combined with chemotherapy or radiation to improve outcomes and make cancer cells more visible to the immune system.

Most approved lung cancer immunotherapies are “checkpoint inhibitors.” These drugs target PD-1 or PD-L1 (such as pembrolizumab, nivolumab, atezolizumab, durvalumab) and, in select situations, CTLA-4 (ipilimumab). Research is also exploring vaccines and cell-based therapies, which are largely available through clinical trials.

How It Works: Checkpoints, Vaccines, and More

Checkpoint blockade

Cancer cells can hide by engaging immune checkpoints—signals that tell T cells to stand down. PD-1/PD-L1 and CTLA-4 are two key checkpoints. Drugs that block these signals “release the brakes,” allowing T cells to attack. In people whose tumors express high levels of PD-L1, first-line pembrolizumab has shown a significant overall-survival advantage over chemotherapy alone (KEYNOTE-024).

When PD-L1 is low or absent, combining immunotherapy with chemotherapy can improve results. For nonsquamous NSCLC, adding pembrolizumab to platinum-pemetrexed cut the risk of death compared with chemotherapy alone (KEYNOTE-189).

Vaccines and cellular therapies

Cancer vaccines aim to train the immune system against tumor-specific markers. Cellular therapies, like tumor-infiltrating lymphocytes or engineered T cells, are under active study for lung cancer but are not yet routine. You can search enrolling studies on ClinicalTrials.gov.

Immune modulators and combinations

Therapies that reshape the tumor microenvironment, or the use of radiation to release tumor antigens, may amplify immune responses. These strategies are typically explored in clinical trials or selected clinical scenarios.

When to Choose Immunotherapy vs. Chemotherapy

The decision depends on cancer type, biomarkers, pace of disease, other health conditions, and your goals. Common scenarios include:

  • High PD-L1 (≥50%) in metastatic NSCLC: Pembrolizumab alone is often preferred, based on survival benefits over chemotherapy (see KEYNOTE-024).
  • PD-L1 1–49% or PD-L1 negative: Chemo-immunotherapy combinations are commonly used (e.g., platinum + pemetrexed + pembrolizumab for nonsquamous NSCLC, supported by KEYNOTE-189).
  • Stage III unresectable NSCLC after chemoradiation: Durvalumab consolidation can extend progression-free and overall survival (PACIFIC trial).
  • Extensive-stage small cell lung cancer (SCLC): Adding an immune checkpoint inhibitor to chemotherapy has improved overall survival in clinical trials.
  • Actionable driver mutations (EGFR, ALK, ROS1, etc.): Targeted therapy is usually favored first. Immunotherapy alone is less effective here and may carry higher toxicity if used too close to certain tyrosine kinase inhibitors.
  • Need for rapid tumor shrinkage: Chemotherapy often works faster; combinations may balance speed and durability.
  • Autoimmune disease, transplant, or chronic high-dose steroids: Immunotherapy may be risky; decisions are individualized with your oncology team and relevant specialists.

Eligibility and Testing

Before starting immunotherapy, your team will confirm the cancer type (NSCLC or SCLC), stage, and biomarker profile. For NSCLC, PD-L1 testing helps guide whether to use immunotherapy alone or with chemotherapy. Comprehensive genomic profiling looks for “driver” alterations (EGFR, ALK, ROS1, MET, RET, BRAF, KRAS G12C, NTRK) that may point to targeted therapies first.

Other biomarkers are of interest but less routinely used in lung cancer: tumor mutational burden (TMB), MSI-high/dMMR (uncommon in lung cancer but can predict response to certain checkpoint inhibitors), and gene expression signatures. Your oncologist will interpret these in the context of your overall health and goals.

What Treatment Looks Like

Checkpoint inhibitors are given by IV infusion, typically every 3–6 weeks depending on the drug and dose. Many regimens continue for up to two years or until the cancer progresses or side effects require stopping. You’ll have periodic scans (often every 6–12 weeks) to assess response. Occasionally, tumors can appear to grow before shrinking (“pseudoprogression”), so clinicians interpret scans alongside symptoms and lab trends.

Common agents include pembrolizumab, nivolumab, atezolizumab, and durvalumab. For stage III NSCLC treated with chemoradiation, a year of durvalumab consolidation after recovery from radiation is standard in eligible patients. For extensive-stage SCLC, an immune checkpoint inhibitor is added to initial chemotherapy in many cases.

Side Effects: What to Watch For

Because immunotherapy activates the immune system, side effects stem from inflammation of normal tissues—called immune-related adverse events (irAEs). Most are manageable when recognized early. Learn more about these reactions from the National Cancer Institute’s overview here.

  • Common: Fatigue, rash/itching, thyroid changes (hypo- or hyperthyroidism), joint aches.
  • Less common but important: Pneumonitis (inflammation of the lungs), colitis (diarrhea), hepatitis (liver enzyme rise), hypophysitis (pituitary), adrenal insufficiency, type 1 diabetes, kidney inflammation, nerve or heart inflammation.
  • Red flags to report immediately: New/worsening shortness of breath or cough, severe diarrhea, yellowing of eyes/skin, severe headache, extreme fatigue, chest pain, or high fevers.

Management often involves pausing treatment and using corticosteroids or other immune dampening medicines. Prior chest radiation can increase the risk of pneumonitis; your care team will monitor symptoms closely.

Costs, Access, and Clinical Trials

Immunotherapy drugs are widely available and commonly covered by insurance for approved indications, but out-of-pocket costs vary. Your clinic’s financial counselor can help navigate coverage and manufacturer support programs. For official drug information and approvals in this area, see the FDA’s immuno-oncology resources here.

If you’re considering clinical trials—for access to next-generation therapies or novel combinations—start with the U.S. government’s registry at ClinicalTrials.gov, and ask your oncologist which studies fit your cancer type, stage, and biomarker profile.

FAQs

Can immunotherapy cure lung cancer?

Cures are uncommon in metastatic lung cancer, but some people achieve long-lasting remissions, especially those who respond early and remain on therapy for a sustained period.

How long does treatment last?

Many checkpoint inhibitor regimens continue for up to two years if the cancer remains controlled and side effects are manageable. Duration may be tailored to your situation.

Is it safer than chemotherapy?

Side effects are different—not necessarily “safer” across the board. Fewer hair loss or nausea issues, but risks of organ inflammation require vigilance and prompt reporting.

What if I have an autoimmune disease?

Immunotherapy can flare autoimmune conditions. Decisions are individualized; your oncologist may coordinate with your specialist and consider alternatives or added monitoring.

Sources